6XP.F XSPRAY PHARMA AB
- Market cap
- EUR 55.6M
- P/E
- -
- P/B
- 1.01x
- ROE
- -25.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 6XP.F undervalued?
Graham numberThe Graham number of XSPRAY PHARMA AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
XSPRAY PHARMA AB fundamental analysis
No fundamental analysis for XSPRAY PHARMA AB yet.
XSPRAY PHARMA AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About XSPRAY PHARMA AB
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib fo…
Full company profileXSPRAY PHARMA AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
XSPRAY PHARMA AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -131M | -181M | -283M | -159M | -132M |
| EBITDA | -122M | -170M | -275M | -149M | -126M |
| Net Income | -132M | -180M | -286M | -171M | -153M |
| EPS | -5.58 | -5.58 | -7.55 | -4.11 | -3.22 |
| Balance Sheet | |||||
| Total Assets | 585M | 765M | 796M | 769M | 719M |
| Total Liabilities | 29.4M | 71.9M | 173M | 165M | 121M |
| Shareholders' Equity | 556M | 693M | 623M | 605M | 598M |
| Cash & Short-term Investments | 120M | 166M | 208M | 154M | 88.8M |
| Cash Flow | |||||
| Operating Cash Flow | -110M | -203M | -222M | -193M | -135M |
| Capital Expenditure | 128M | 54.1M | 42.1M | 29.2M | 22.7M |
| Free Cash Flow | -238M | -257M | -265M | -222M | -157M |
| Ratios | |||||
| ROE | -23.7% | -25.9% | -45.8% | -28.4% | -25.5% |
| ROA | -22.5% | -23.5% | -35.9% | -22.3% | -21.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
XSPRAY PHARMA AB dividends
XSPRAY PHARMA AB has not paid dividends in the last 4 fiscal years.
Who owns XSPRAY PHARMA AB
- Insiders 22.74%
- Institutions 43.94%
- Public & others 33.32%
- Shares outstanding 47.4M
- Free float 33.9M
XSPRAY PHARMA AB company profile
- Company name
- XSPRAY PHARMA AB
- Ticker
- 6XP.F
- ISIN
- SE0009973563
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 24
- Fiscal year end
- December
- Address
- Scheeles väg 2, Solna, Sweden, 171 65
- Phone
- 46 87 30 37 00
- Website
- xspraypharma.com
About XSPRAY PHARMA AB
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partnership agreements with EVERSANA for the commercialization of Dasynoc. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.
XSPRAY PHARMA AB management
6- Dr. Per Andersson Ph.D.Chief Scientific Officer · born 1967
- Mr. Blake LeitchChief Executive Officer · born 1975
- Dr. Mustafa Demirbüker Ph.D.Co-Founder and Science Director
- Mr. Niklas AdenborgChief Financial Officer · born 1992
- Ms. Linda GlimbergChief Operating Officer · born 1974
- Dr. Mikael Von Euler-ChelpinChief Medical Officer · born 1953